65,437 trials
Papulopustular Rosacea
Primary: Absolute Change From Baseline in Inflammatory Lesion Count at Week 40 — 23.0; 22.5 Lesions
Overweight · Obesity · Diabetes
Primary: Change in Body Weight — -1.7; -.2; -4.3; -3.0 pounds — p=.296
Solid Tumors and Lymphomas
Primary: Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Hypertension · Healthy
Primary: Aortic Blood Pressure — 5; 6; 4; 4 mmHg — p=<0.001
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis — -4.1 percent change
Graft vs Host Disease · Hematopoietic Stem Cell Transplantation
Primary: Percentage of Patients With Grade II-IV Acute GvHD by Day +100 Following Transplant — 94.4 percentage of participants
S. Aureus Oropharyngeal Colonization
Primary: Number of Participants With Eradiction of S. Aureus From the Oropharyngeal at 7 Days — 18; 7 Participants
Sinusitis
Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100
Neoplasms, Advanced Solid
Primary: Part 1, Cmax: Maximum Observed Plasma Concentration for TAK-931 Tablets in Reference to PIC — 251.45; 270.09 nanogram per milliliter (ng/mL)
Complicated Urinary Tract Infections
Primary: Percentage of Participants With Overall Success — 301; 325 Participants
Human Immunodeficiency Virus
Primary: Changes in sCD14 After 9 Months of Treatment With Aspirin or Atorvastatin — -0.131; -0.09 pg/mL — p=>0.05
Lymphoma · Disorder Related to Bone Marrow Transplantation
Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants
Merkel Cell Carcinoma
Primary: MLN01283 Maximum Tolerated Dose (MTD) [Phase I] — 3 mg
Alcohol Use Disorder · Posttraumatic Stress Disorder (PTSD)
Primary: Change in Percent Drinking Days (PDD) (Visit 8 PDD - Visit 2 PDD) — -37; -9; -14; -15 percentage of drinking days
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts — 7.3; 6.2; 8.2; 5.4 percentage of participants